% | $
Quotes you view appear here for quick access.

Cannabis Science, Inc. Message Board

  • hlbetz hlbetz Nov 1, 2012 2:09 PM Flag

    Cannabis Science Appoints Christopher Meenan MS, MBA as Executive Vice President of Product Research and Development

    COLORADO SPRINGS, Colo., Nov. 1, 2012 /PRNewswire via COMTEX/ -- Cannabis Science Inc., (CBIS) announced today the appointment of Christopher Meenan MS., MBA, as Executive Vice President of Product Research and Development, adding significant expertise to Cannabis Science's investigation of CS-TATI-1 for Karposi's Sarcoma and CS-S/BCC-1 for Basal and Squamous Cell Carcinomas, the Company's lead initiatives entering initial clinical development.

    Christopher Meenan joins Dr. Roscoe Moore, former U.S. Assistant Attorney General, Dr. Ronald Sekura PhD. former Food and Drug Administration (FDA) Research Chemist, Center for Biologics Evaluation and Review, Dr. Dorothy Bray former Director, Clinical Development HIV, GlaxoSmithKline, UK, and Dr. J. Thomas August Professor, Pharmacology and Molecular Sciences, and Oncology at The Johns Hopkins University School of Medicine.

    "We are pleased to announce Christopher Meenan's appointment as Vice President of Product Research and Development of Cannabis Science. Mr. Meenan's expertise in drug development will accelerate our investigation of Phytocannabinoids for the treatment of Karposi's Sarcoma and Basal and Squamous Cell Carcinomas," stated, Dr. Robert Melamede, President & CEO, Cannabis Science Inc.

    Cannabis Science is dedicated to the research and development of phytocannabinoid-based therapeutics. The Company's initial focus is to treat infectious diseases and Cancer. CS-TATI-1, Cannabis Science's lead compound is, in development as an HIV TAT inhibitor to reduce HIV replication as well as a topical cannabis-based preparations CS-S/BCC-1 for the treatment of basal and squamous cell carcinomas.

    "We have rapidly assembled a team of dedicated experts to accelerate the Cannabis Science investigational pipeline. We anticipate the appointment of a Chief Medical Officer and a Chief Scientific Officer within the first quarter of the New Year to initiate the required regulatory process in the United States and Europe to enter into human clinical studies in HIV and Cancer patients," concludes, Dr. Melamede.

    About Christopher Meenan MS, MBA

    Mr. Meenan began his professional career in 1991 working for Unigene Laboratories as a molecular biologist helping to create the company's patented recombinant production technologies. He also worked in transferring manufacturing technologies to in house and external large-scale cGMP facilities. Christopher held several positions within the R&D unit at Unigene including Senior Scientist for Molecular Biology and Fermentation Development where he continued to advance the manufacturing capabilities of the company's biologic products. After receiving an MBA in 2007 he moved into a Director role in business development establishing an out licensing program for the company's manufacturing and drug delivery technologies along with evaluation of external products for in licensing.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
0.0143-0.0012(-7.74%)12:41 PMEDT